Chris Bradley: Better Science for Longevity
In this episode, host Rizim Tom chats with Chris Bradley of MatterBio about the science of longevity, focusing on how genomic damage drives the hallmarks of aging. Bradley explains that while cells constantly renew, DNA damage from internal sources like reactive oxygen species and external toxins accumulates, impairing repair mechanisms and accelerating aging. He outlines the main types of DNA damage—single- and double-strand breaks, intercalation, and base mismatches—and argues that targeting genome stability is the most upstream strategy for extending healthspan. The discussion also touches on recent medical advances, such as therapies that have effectively cured 80% of cystic fibrosis cases, illustrating how biotech is already improving lifespan.
Micro-Cages Enable Precise Manipulation of Cell Clusters
These micro-cages are designed to hold and manipulate tiny cell clusters in miniaturized lab-on-a-chip devices. https://spectrum.ieee.org/lab-on-a-chip-grippers?share_id=9241061
EGFR Vs. ALK: How Molecular Profiling Defines Lung Cancer Treatment
Comprehensive molecular profiling of two stage IV NSCLC patients revealed distinct driver alterations—an EGFR exon 19 deletion in one and an EML4‑ALK fusion in the other—prompting personalized first‑line therapy with osimertinib and alectinib respectively. Both patients experienced rapid symptomatic improvement and enhanced...
Re: Standard Chemoradiotherapy with Concurrent and Adjuvant Camrelizumab in Patients with High Risk Nasopharyngeal Carcinoma: Multicentre, Randomised, Open Label, Phase...
A phase‑3 BMJ trial reported that adding camrelizumab to standard chemoradiotherapy improved 36‑month progression‑free, distant‑metastasis‑free and locoregional‑recurrence‑free survival in high‑risk nasopharyngeal carcinoma. The protocol combined two concurrent cycles with 17 adjuvant cycles, yet only 61.9% of patients completed the full...
Zydus Lifesciences’ Anaemia Drug Desidustat Gets China Approval
Zydus Lifesciences has received NMPA approval for its oral anaemia drug Desidustat, targeting renal anaemia in adult chronic kidney disease patients who are not on dialysis. The therapy, a hypoxia‑inducible factor‑prolyl hydroxylase inhibitor, demonstrated efficacy and safety in Chinese Phase III...
First Human Age‑Reversal Trial Targets Whole‑Body Reset
The first human age-reversal trial is officially happening. But before the FDA cleared it, Harvard professor David Sinclair had to pull off a mice experiment most scientists thought was impossible: "These mice had their optic nerve regenerated. We were able to...
Drug Patents: Near-Term Generic Threat, Mid-Term Safeguards, Tirzepat
AI: Short-Term Cliffs (0-3 years remaining): Drugs like sacubitril/valsartan, dapagliflozin, pembrolizumab, ocrelizumab, daratumumab, and apixaban face imminent generic/biosimilar pressure Mid-Term Protection (4-7 years): Risankizumab and dupilumab have solid runway, supported by ongoing label expansions. Long-Term (8+ years): Tirzepatide's robust patents position it...
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency...
YolTech Therapeutics announced FDA approval of its IND for YOLT-202, an in vivo adenine base‑editing therapy targeting Alpha‑1 Antitrypsin Deficiency. The clearance permits an open‑label, single‑dose Phase 2/3 expansion study across the U.S. and other regions. In the ongoing first‑in‑human trial,...
FoxO3a Boost in Dentate Gyrus Eases Stress‑induced Depression
Overexpression of FoxO3a in the dentate gyrus alleviates CUS-induced anxiety- and depression-like behaviors and cognitive impairment https://t.co/p2t18NRkew
A Lab Mistake at Cambridge Reveals a Powerful New Way to Modify Drug Molecules
Cambridge chemists have unveiled a light‑driven “anti‑Friedel‑Crafts” reaction that forms carbon‑carbon bonds using only LED illumination at ambient temperature. The metal‑free method allows precise, late‑stage modifications of complex drug molecules, cutting months of multistep synthesis. Tested on a broad set...
Immune Checkpoint Dysregulation Drives Pediatric Bronchiolitis Severity
A new multicenter study links dysregulated immune checkpoint pathways, especially PD‑1/PD‑L1 and CTLA‑4, to heightened severity in pediatric bronchiolitis. Researchers measured checkpoint molecule expression in airway samples from 312 infants and found that higher PD‑1 levels correlated with increased IL‑6,...
EpiAge‑R Integrates Epigenetic Clocks, Resilience, and Multi‑omics Ageing
Epigenetic Clocks, Resilience, and Multi-Omics Ageing: A Review and the EpiAge-R Conceptual Framework The hierarchical architecture of the EpiAge-R framework... https://t.co/YpwDdLI7wo https://t.co/Uid3kNzDHr
Pretzel Therapeutics Presents PX578 Data Supporting POLG Disease Treatment
Pretzel Therapeutics presented preclinical data for its investigational small‑molecule PX578 at the 2026 MDA Clinical and Scientific Conference. The drug is designed to activate the mitochondrial DNA polymerase gamma (POLG) and restore mitochondrial DNA levels in patients with mitochondrial DNA...
What’s New Pussycat? FDA Assists Drug Sponsors Requesting New Clinical Investigation Exclusivity
The FDA released draft Q&A guidance that clarifies how drug sponsors can qualify for three‑year non‑patent exclusivity by conducting a “new clinical investigation.” It defines a new study as a human, non‑bioavailability trial whose results have not been previously relied...
Rare Disease Spotlight: Friedreich Ataxia Moves Beyond Mitochondrial Bandages
Friedreich ataxia (FA) received its first FDA‑approved therapy in 2023 when omaveloxolone, marketed as Skyclarys, earned accelerated approval. Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals secured the drug and highlighted the market’s appetite for rare‑disease assets. Skyclarys works by activating the...
Network-Based Prediction of Drug Combinations with Quantum Annealing
The study introduces a quantum‑annealing algorithm that predicts effective drug combinations by casting the problem as a quadratic unconstrained binary optimisation (QUBO). It leverages the network‑medicine concept of disease modules and the “Complementary Exposure” principle, which seeks drugs that hit...
Real-Time PCR–Based Detection of Mycoplasma Agalactiae in Sheep Bulk Tank Milk to Support Flock-Level Epidemiology
A real‑time PCR assay for detecting Mycoplasma agalactiae in sheep bulk‑tank milk was developed and validated, showing high specificity and sensitivity. The test was deployed across more than 900 dairy sheep farms in Sardinia, revealing widespread but generally low‑level prevalence...
Horse IVF Milestone in Florida: Frozen-Thawed Sperm Fertilizes an Egg
University of Florida researchers have achieved the first successful in‑vitro fertilization of a horse egg using frozen‑thawed sperm. The study showed that frozen‑thawed stallion sperm, after undergoing stress‑induced capacitation, fertilized the oocyte more effectively than fresh or chilled sperm. This...
Adenine Methylation Forms New Linear Brain Aging Clock
A completely novel axis of epigenetic aging. N6-methyldeoxyadenosine (N6medA), i.e. NOT the usual 5 methyl cytosine, increases linearly with age in human prefrontal cortex (r=0.95). Genome-wide profiling reveals age-associated ADENINE methylation changes reminiscent of classic CpG based epigenetic clocks. Abdur...
Quantifying Pathway Identifiability Under Partial Metabolomics for Measurement Prioritization
The study introduces an operator‑based framework to assess pathway identifiability when metabolite coverage is incomplete. It aligns condition‑specific pathway graphs using a Johnson‑Lindenstrauss stabilized fused Gromov‑Wasserstein (JL‑FGW) operator and quantifies ambiguity via a composite functional that blends transport entropy, alignment...
No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions
The FDA on March 10 expanded leucovorin’s label to cover a very rare genetic folate‑transport disorder, not autism. Earlier, Commissioner Marty Makary suggested the drug could help “hundreds of thousands of kids” with autism, creating expectations of a broad approval. FactCheck.org...
How Dompé Is Innovating in Neuro-Ophthalmology with the FDA’s CNPV Program
Dompe, a privately owned biopharma, is advancing an intranasal nerve growth factor (NGF) therapy to treat non‑arteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden vision loss affecting roughly 6,000 U.S. patients annually. The approach leverages NGF’s neuroprotective...
Bacterial Strain Breaks Decades-Old Bottleneck in Chemotherapy Drug Manufacturing
An international research team has engineered a bacterial strain that boosts doxorubicin output by 180% compared with current industrial methods, overcoming three long‑standing bottlenecks—insufficient redox partners, drug‑binding “sponge” proteins, and suboptimal enzyme positioning. The findings, published in Nature Communications, detail...
Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
During the COVID‑19 pandemic, vaccine makers pledged not to enforce mRNA‑related patents, but that restraint has ended, sparking a wave of litigation over lipid nanoparticle (LNP) and mRNA payload technologies. Major cases include Alnylam’s suits against Pfizer and BioNTech, Arbutus’s...
University of Calgary Researchers Use AI to Hunt New Treatments for Cattle Parasites
University of Calgary researchers have secured a $1.4 million NSERC grant to apply AI‑driven genomics in the hunt for new anti‑parasitic drugs targeting roundworms in beef cattle. By sequencing helminth genomes and screening large chemical libraries, the team has already identified...
Bimatoprost Implant Reduces IOP, Improves Vision at 12 Months
SpyGlass Pharma’s Bimatoprost Drug Pad‑IOL System demonstrated significant intra‑ocular pressure (IOP) reductions and vision gains in a phase 1/2 trial of 104 patients with open‑angle glaucoma or ocular hypertension undergoing cataract surgery. At 12 months, the 78 µg dose lowered mean IOP 34%...
FDA Approves Cosentyx for Pediatric Hidradenitis Suppurativa
The U.S. Food and Drug Administration has approved Novartis' secukinumab, marketed as Cosentyx, for adolescents aged 12 and older with moderate‑to‑severe hidradenitis suppurativa (HS). This marks the first IL‑17A inhibitor cleared for a pediatric indication, extending the drug’s adult HS...
Ultrasound-Based Approach to Delivering Potent Drugs Into Cancer Cells Shows Promise in Benchtop Experiments
Duke engineers introduced SonoPIN, an ultrasound‑driven platform that bursts cancer‑targeted microbubbles to create temporary pores in cell membranes. The technique allowed large PROTAC drugs to enter tumor cells, killing 50% of them while sparing 99% of healthy cells in benchtop...
Kenai: Off-the-Shelf Parkinson’s Progenitors with Precision Transplant Tech
Kenai, a new allogeneic cell‑therapy company, is developing off‑the‑shelf iPSC‑derived progenitor cells for Parkinson’s disease, paired with a precision brain‑delivery platform that uses real‑time functional imaging. The approach builds on Japan’s recent approvals of iPSC‑based Parkinson’s treatments and aims to...
A Preprint Claiming Exceptional Extension of Life in Mice via a Telomere Transfer Mechanism
A recent preprint from biotech startup Sentcell claims that adoptive transfer of engineered CD4+ T cells can generate extracellular “telomere Rivers,” which purportedly extend median mouse lifespan by about 17 months, with some animals living nearly five years. The authors...
Jeonbuk National University Researchers Develop DDINet for Drug-Drug Interaction Prediction
Researchers at Jeonbuk National University have unveiled DDINet, a lightweight neural network designed to predict drug‑drug interactions (DDIs) for previously unseen compounds. The model employs five fully‑connected layers and molecular fingerprints, with Morgan fingerprints delivering the best results. Using a...
Testing Parsley Promoter RUBY in Stable Petunia Transformation
Okee, two more cultivars to sterilize and transform and I'm done for the day. Let's rile up the agro and get this done. Also among the stuff I need to test for work, I'm going to see if this parsley...
Vaccination Boosts Survival in Multiple Myeloma Patients
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/L7r9caCcGN
Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy
A West Health‑Gallup survey reveals that over 82 million Americans have reduced daily spending to afford healthcare, highlighting deepening affordability pressures across income levels. The FDA has broadened GSK’s RSV vaccine Arexvy to cover high‑risk adults aged 18‑49, a group responsible...
MRD‑Negative Patients May Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
ODAC Backs MRD as Early Endpoint for Myeloma Approvals
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/W3vwHRTzhE
Ketamine Therapy for Chronic Pain and Substance Misuse
Recent peer‑reviewed study of 20 adults with chronic pain and substance misuse found ketamine therapy improved pain, mood, and dependence scores. The integrated treatment was delivered within a coordinated pain program, highlighting benefits of interdisciplinary care. Findings suggest ketamine can...
Testing Ubiquitin Promoter for Stable Petunia Transformation
Alright, Alice 24-0001 petunia bits co-culturing with Agribacterium strain Gv3101 carrying a PcUBI4::RUBY::THSP construct. Testing out this ubiquitin promoter for stable transformation to avoid silencing. These will bake at 30°C until Monday and then transfered to selection. 🤞 https://t.co/SO1EKELMgU
Epigenetic Therapy Marks New Era in Glaucoma Treatment
Great to see ophthlamologists adopting epigenetic modifications and resets to treat eye diseases like glaucoma. A paradigm shift in medicine https://t.co/g2gr3WVpkf https://t.co/6gbBVHJuXI
Money Raised by Biopharma
Researchers at INSERM uncovered hypothalamic tanycytes as a previously unknown tau‑clearing pathway, opening fresh therapeutic avenues for Alzheimer’s and related tauopathies. Merck Sharp & Dohme (MSD) announced the synthesis and pre‑clinical testing of novel PET tracers that bind α‑synuclein, aiming...
Shilpa Biologicals, mAbTree Program Targets Immune Pathway in Rare Blood Cancers
Shilpa Biologicals and mAbTree Biologics received FDA orphan drug designation for an investigational monoclonal antibody that targets an immune‑evasion pathway in essential thrombocythemia and polycythemia vera. The designation validates the novel mechanism and accelerates plans for IND‑enabling studies and first‑in‑human...
Parsley Uniquitin Promoter Matches 35S at 72
Great signal at the 72hr mark which is peak RUBY accumulation. Parsley uniquitin promoter as reliable as 35s for my projects. Glory be. Here's the expired patent: https://t.co/njN84BkHho https://t.co/kDfx1RoenJ
March 13 Policy Watch: FDA Streamlines Its Process for Approving Biosimilar Drugs
The FDA released draft guidance that lets biosimilar developers use foreign comparator data and, in some cases, replace clinical studies with chemical analysis, potentially cutting development costs by $20 million. Simultaneously, the agency launched the Adverse Event Monitoring System (AEMS), a...
China Biotech Receives FDA Approval for First Cell Therapy Trial
With FDA go ahead, a China #biotech notches a first in cell therapy testing https://t.co/QorwJmou8w by @realJacobBell $XENE $BHVN
Bacteria 4D Simulation, Safer Large Gene Insertion, uniQure Roller Coaster
The J. Craig Venter Institute unveiled a 4D, nanoscale simulation that tracks the entire life cycle of a minimal bacterial cell, marking a milestone for synthetic biology. A new gene‑editing platform designs DNA donors that dodge immune detection, enabling safer,...
Tahoe Therapeutics Builds Record Single-Cell Atlas Using Automated Pipetting Technology
San Francisco biotech Tahoe Therapeutics is building the world’s largest single‑cell atlas of cell‑chemical interactions, leveraging Integra Biosciences’ Assist Plus pipetting robot, Parse Biosciences’ Evercode scRNA‑seq kits, and its own AI analytics. Automation has increased single‑cell preparation throughput more than fivefold...
Cancer Vaccines Show Promise for Hard-to-Treat Tumors
Cancer vaccines are showing marked efficacy vs refractory cancers and are going to be part of the future Rx armamentarium. Beyond that, ultimately, for prevention in high-risk individuals. A new stellar review @NatureMedicine https://t.co/PhtdZDtSBl https://t.co/okmwCD8AyB
Renal Cell Carcinoma Strategic Intelligence Report
The latest ASCO GU strategic intelligence report spotlights renal cell carcinoma (RCC) as a field entering a transformative phase. Analysts highlight emerging biomarkers, novel HIF‑2α inhibitors, and evolving immunotherapy combinations as potential high‑impact developments. While these advances promise to reshape...
Theriva Biologics Reports 2025 Results and Pipeline Progress
Theriva Biologics closed 2025 with $13.1 million in cash, rising to $15.2 million by February 2026, enough to fund operations into the first quarter of 2027. The company reported a net loss of $25.3 million, a modest improvement as R&D spend fell while...
Amyloid Antibody Therapy Triggers 100 Microhemorrhages in APOE4 Patient
100 brain microhemorrhages in a patient with cerebral amyloid angiopathy and 2 copies of APOE4 after amyloid antibody therapy https://t.co/ASpVuijFNW https://t.co/hdtwtv1usq